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DISST ID program features 
1. Can use minute or second resolution 
2. Can recognise best parameter identification 
method for given input data. All of the methods 
presented in Docherty et al. [9, 10] can be used 
3. Allows precise time input 
4. Allows differing dosing 
5. Provides plots of glucose concentration, insulin 
concentration and pre-hepatic insulin secretion 
6. Outputs all participant specific estimated, a-
priori and identified parameter values 
7. Identifies assay error and can automatically 
ignore bad assays during parameter 
identification, if desired 
• Results can be saved to csv 
• Batch files can be processed 
2 1 
3 4 
6 
5 
7 
The Dynamic Insulin Sensitivity and Secretion Test (DISST) 
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AIM: To provide a low-cost insulin sensitivity test, while 
maintaining rich information content.  
 
The dynamic insulin sensitivity and secretion test (DISST) was designed to capture 
insulin secretion kinetics and glucose dynamics with a less clinically intense 
protocol than the euglycaemic clamp (EIC), or IVGTT. DISTq was developed to 
enable real-time and low-cost identification of insulin sensitivity by using only 
glucose data.  While the DISST directly measures the participant’s insulin response 
to the test stimulus, DISTq estimates the response with a series of population-
derived relationships 
 
The DISST and EIC were undertaken by 50 heterogeneous participants and the 
insulin sensitivity values of the DISST, DISTq and EIC were compared 
OUTCOMES: Correlation between the gold standard EIC 
and DISST and DISTq were R=0.81 and R=0.76, respectively 
 
The DISST 50th percentile under-estimation of the EIC was -10.6% (IQR -26.8% to 
7%), and ROC c-unit was 0.96. The 50th percentile over-estimation produced by 
DISTq was 13.4% (IQR -24.7 to 33.1%), and the ROC c-unit was 0.84. Participant 
tolerance of the DISST protocol was very high. No symptomatic hyperglycaemic 
incidents were noted. 
 
The DISST was capable of distinguishing clinically important differences in 
insulin secretion that the EIC could not.  
BARRIER TO UPTAKE: The DISST and DISTq parameter 
identification methods are sometimes considered too 
complex to apply. 
 
Many groups with a primary focus on clinical research can lack access to parameter 
identification software or mathematical expertise. For the DISST or the DISTq to be 
used by such groups, some provision must be made for parameter identification.  
 
SOLUTION: A stand-alone, simple-to-use computer program could 
allow any research group to use the DISST or DISTq. 
 
 
 
t=30  
mins Glucose bolus 
@ t=0 
Insulin 
bolus 
@ t=10 
Clinical protocol 
The DISST is similar to the insulin-modified intravenous glucose 
tolerance test (IM-IVGTT) with some important distinctions: 
• Uses comparatively low-dose to avoid saturation of insulin-
mediated uptake of glucose [1, 2] 
• Uses in-frequently sampled protocol with a lower overall 
duration 
• Requires one skin puncture 
• 5 samples are assayed for C-peptide as well as glucose and 
insulin 
Modelling Strategy 
The comparatively low clinical intensity of the DISST requires robust 
modelling and parameter identification approaches to obtain clinically 
relevant parameter values. In particular: 
• C-peptide assays are used to obtain insulin secretion profiles using the 
deconvolution process of Van Cauter et al. [3] 
• Insulin pharmacokinetics between the plasma and interstitium are 
directly modelled with additional resolution provided by insulin 
secretion profiles 
• Glucose decay is modelled with a single parameter, insulin sensitivity, to 
maximise identification stability [4, 5] 
• Parameter identification is undertaken by the iterative integral method 
[6, 7] 
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DISTq does not use insulin or C-peptide assays, 
and thus must estimate the participant’s 
insulinaemic response to the DISST test stimulus. 
There are no strong a-priori relationships for the 
factors that define insulin kinetics. However, 
these factors have relatively strong relationships 
with insulin sensitivity. Hence, the iterative 
process summarised in steps 1-5 allows 
convergence to an accurate insulin sensitivity 
value.  
The process is explained thoroughly in Docherty 
et al. [6, 8] 
DISTq Parameter Identification 
1. Define population average insulin sensitivity 
(10x10-4 L.mU-1.min-1) 
2. Estimate basal insulin, hepatic insulin 
clearance, and a pre-hepatic insulin secretion 
profile using estimated insulin sensitivity 
value and population-based equations 
3. Simulate model-based interstitial insulin 
profile using estimated values 
4. Identify insulin sensitivity with simulated 
interstitial insulin profile and measured 
glucose data 
5. Iterate steps 2-4 updating insulin sensitivity 
until convergence 
 
DISST and DISTq represent two disparate methods of 
measuring insulin sensitivity from dynamic insulin 
sensitivity data. While the test stimulus is common between 
the methods, they have very different assay costs. Hence, a 
series of methods were proposed to provide a compromise 
between the distinct strategies of the DISST and the DISTq. 
These methods allow optimal test selection for a wide range 
of clinical applications [9, 10].  
Finally the common protocol means that if a lower-
resolution test response is too close to a clinical threshold, 
the samples taken can be re-assayed to allow a higher 
resolution test, without the need for an additional clinical 
protocol. 
Hybrid Methods 
